Nomifensine and hemolytic anemia — experience of a post-marketing alert

摘要: The antidepressant nomifensine was withdrawn worldwide by the manufacturer in January 1986 following a rising incidence of reports acute immune hemolytic anemia with serious clinical sequelae, including number fatalities. This short report describes chronology events leading up to drug's withdrawal one country, United Kingdom, 9 years after it first made available. known related prescription data and showed that risk-benefit ratio tipped against continued availability drug only latter part 1985, shortly before withdrawn. Factors increased reporting adverse are discussed, but awareness prescribers drug-related their willingness them as result medical literature media reports, publications Committee on Safety Medicines Yellow Card data, thought have been major contributors.